Table 1.
Baseline characteristics of the study population by pre-diagnosis recreational physical activity level, the Sister Study.
| Baseline characteristics | Overall (n=180) | Pre-diagnosis recreational physical activity, MET-hrs/wk | ||
|---|---|---|---|---|
| <3.0 (n=60) | 3.0 – <13.2 (n=60) | ≥13.2 (n=60) | ||
| Pre-diagnosis recreational physical activity, MET-hrs/wk mean ± SD | 13.4 ± 17.8 | 0.8 ± 1.0 | 8.2 ± 3.3 | 31.6 ± 21.8 |
| Pre-diagnosis total physical activity, MET-hrs/wk mean ± SD | 48.4 ± 31.6 | 31.0 ± 21.8 | 44.0 ± 19.8 | 70.2 ± 36.9 |
| Age at baseline, yr mean ± SD | 53.4 ± 8.0 | 52.2 ± 7.2 | 54.0 ± 7.5 | 54.1 ± 9.1 |
| Age at BCa diagnosis, yr mean ± SD | 60.8 ± 8.8 | 59.2 ± 8.0 | 61.9 ± 8.3 | 61.3 ± 10.0 |
| Interval from baseline to BCa diagnosis, n (%) | ||||
| 0.5 – <5 yrs | 49 (27.2) | 16 (26.7) | 14 (23.3) | 19 (31.7) |
| 5 – <10 yrs | 80 (44.5) | 33 (55.0) | 21 (35.0) | 26 (43.3) |
| ≥10 yrs | 51 (28.3) | 11 (18.3) | 25 (41.7) | 15 (25.0) |
| Race/Ethnicity, n (%) | ||||
| Non-Hispanic White | 139 (77.2) | 41 (68.3) | 49 (81.7) | 49 (81.7) |
| Non-Hispanic Black / African American | 24 (13.3) | 12 (20.0) | 7 (11.7) | 5 (8.3) |
| Hispanic / Latina | 13 (7.2) | 5 (8.3) | 3 (5.0) | 5 (8.3) |
| Other | 4 (2.2) | 2 (3.3) | 1 (1.7) | 1 (1.7) |
| * BMI, n (%) | ||||
| <25 kg/m2 | 68 (37.8) | 18 (30.0) | 20 (33.3) | 30 (50.0) |
| 25 – <30 kg/m2 | 62 (24.4) | 21 (35.0) | 18 (30.0) | 23 (38.3) |
| ≥30 kg/m2 | 49 (27.2) | 21 (35.0) | 21 (35.0) | 7 (11.7) |
| Alcohol intake, n (%) | ||||
| Nondrinker | 39 (21.7) | 18 (30.0) | 9 (15.0) | 12 (20.0) |
| <1 drink/day | 61 (33.9) | 22 (36.7) | 24 (40.0) | 15 (25.0) |
| ≥1 drink/day | 80 (44.4) | 20 (33.3) | 27 (45.0) | 33 (55.0) |
| Smoking status, n (%) | ||||
| Ever smokers | 110 (61.1) | 41 (68.3) | 35 (58.3) | 34 (56.7) |
| Never smokers | 70 (38.9) | 19 (31.7) | 25 (41.7) | 26 (43.3) |
| Parity, n (%) | ||||
| Nulliparous | 36 (20.0) | 11 (18.3) | 9 (15.0) | 16(26.7) |
| Parous | 144 (80.0) | 49 (81.7) | 51 (85.0) | 44 (73.3) |
| Menopausal status, n (%) | ||||
| Premenopausal | 85 (47.2) | 32 (53.3) | 26 (43.3) | 27 (45.0) |
| Postmenopausal | 95 (52.8) | 28 (46.7) | 34 (56.7) | 33 (55.0) |
| Hormone replacement therapy, n (%) | ||||
| Never use | 118 (65.6) | 40 (66.7) | 36 (60.0) | 42 (70.0) |
| Estrogen use only | 24 (13.3) | 8 (13.3) | 8 (13.3) | 8 (13.3) |
| Progestin use only | 7 (3.9) | 2 (3.3) | 3 (5.0) | 2 (3.3) |
| Estrogen plus progestin use | 31 (17.2) | 10 (16.7) | 13 (21.7) | 8 (13.3) |
| * Tumor grade, n (%) | ||||
| Low | 10 (5.6) | 2 (3.3) | 5 (8.3) | 3 (5.0) |
| Moderate | 63 (35.0) | 22 (36.7) | 20 (33.3) | 21 (35.0) |
| High | 97 (53.9) | 32 (53.3) | 32 (53.3) | 33 (55.0) |
| Tumor stage, n (%) | ||||
| Stage I | 36 (20.0) | 13 (21.7) | 12 (20.0) | 11 (18.3) |
| Stage II | 95 (52.8) | 28 (46.7) | 29 (48.3) | 38 (63.3) |
| Stage III | 49 (27.2) | 19 (31.7) | 19 (31.7) | 11 (18.3) |
| * Tumor receptor status, n (%) | ||||
| HR+ HER2+ | 42 (23.3) | 13 (21.7) | 15 (25.0) | 14 (23.3) |
| HR+ HER2- | 66 (36.7) | 23 (38.3) | 22 (36.7) | 21 (35.0) |
| HR- HER2+ | 17 (9.4) | 7 (11.7) | 5 (8.3) | 5 (8.3) |
| HR- HER2- | 48 (26.7) | 14 (23.3) | 16 (26.7) | 18 (30.0) |
| Receiving Anthracylines chemotherapy, n (%) | 96 (53.3) | 33 (55.0) | 30 (50.0) | 33 (55.0) |
| Receiving Taxanes chemotherapy, n (%) | 169 (93.9) | 58 (96.7) | 54 (90.0) | 57 (95.0) |
| Receiving Platinum agents chemotherapy, n (%) | 56 (31.1) | 18 (30.0) | 20 (33.3) | 18 (30.0) |
| Receiving neoadjuvant biologic therapy, n (%) | 64 (35.6) | 22 (36.7) | 20 (33.3) | 22 (36.7) |
| Trastuzumab + Pertuzumab | 35 (19.4) | 15 (25.0) | 11 (18.3) | 9 (15.0) |
| Trastuzumab only | 23 (12.8) | 6 (10.0) | 8 (18.3) | 9 (15.0) |
| Bevacizumab | 2 (1.1) | 1 (1.7) | 0 | 1 (1.7) |
| Unknown | 4 (2.2) | 0 | 1 (1.7) | 3 (5.0) |
MET=metabolic equivalent task, BCa=breast cancer, SD=standard deviation, BMI=body mass index, HR=hormone receptor, HER2= human epidermal growth factor receptor 2
*
Missing: BMI n=1 (0.6%), tumor grade n=10 (5.5%), tumor receptor status n=7 (3.9%)